Y90, or Yttrium-90 radioembolization, is an innovative and targeted treatment for liver cancer. This minimally invasive procedure involves the use of tiny radioactive beads, called microspheres, that are infused directly into the blood vessels supplying the tumor. Y90 therapy delivers radiation internally to the cancerous cells, maximizing its impact on the tumor while minimizing exposure to healthy surrounding tissue. This approach is particularly effective in treating certain types of liver cancer, offering patients a targeted and well-tolerated alternative. 

Caring Hands

Targeted Liver Cancer Treatment

Female Patient

During and after the procedure

During a Y90 procedure, also known as Yttrium-90 radioembolization, small radioactive beads (microspheres) are precisely delivered into the blood vessels that supply the liver tumor. This is done through a catheter, which is threaded into the hepatic artery under image guidance. The microspheres emit radiation locally, targeting the cancer cells while sparing the surrounding healthy tissue. This approach is effective for liver cancer, as it delivers a concentrated dose of radiation directly to the tumor.

Patients may experience some temporary symptoms, such as fatigue, mild abdominal discomfort, or nausea, which are generally well-tolerated. These effects typically subside within a few days. Serious side effects are uncommon but may include liver damage, infection, or ulcer formation in the stomach or intestines. It’s crucial for patients to discuss potential risks and benefits with their healthcare team before undergoing Y90 therapy. Overall, Y90 radioembolization is recognized for its efficacy and minimal invasiveness in the treatment of liver cancer.

Schedule an Appointment

To discover the treatment path for your specific needs, contact us today to schedule a consultation with one of our board-certified, fellowship-trained interventional oncologists.